RealFeedApp Novartis treatment cuts relapse rates by 35.2%
In two Phase 3 studies, remibrutinib lowered the annualized relapse rate by 35.2% and 31.2% compared to Aubagio, translating to roughly one relapse every 13 years.
- Field
- medicine and diagnostics
- What they did
- A research team from the New Zealand Institute for Advanced Study and the University of British Columbia developed a method to accurately identify which genes are responsible for developing cancer using mutation and gene expression data.
- Why it matters
- This could help doctors diagnose and treat patients with different types of cancer faster and more accurately.
#multiple sclerosis#remibrutinib#clinical trial#relapse rate
